[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypertension-htn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypertension-htn":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,53,83,113,137,157,168,193,220,246,271,292,323,354,395,419,447,473,497,523,549,572,598,629,656],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":36,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100053567","early-phase-1-team-based-shared-decision-making-program-in-cardiovascular-kidney-metabolic-health-100053567",false,"NCT07662616","Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health","Feasibility and Efficacy Pilot of a Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health, Medication Adherence, and Cardiovascular Health","SDM in CKM","Inclusion Criteria:\n\n* Are adults aged 30 to 79 years (to use PREVENT equations to calculate 10- and 30-year risk estimates for total CVD),\n* Are in stage 2 CKM: the presence of metabolic risk factors (hypertension \\[stages 1 and 2\\], hypertriglyceridemia \\[≥135 mg\u002FdL\\], diabetes, Metabolic Equivalents (MetS)\\*) and\u002For Chronic Kidney Disease (CKD) \\[moderate- to high-risk CKD which are stages 1-3 CKD\\]), and\n* Receive primary care at Johns Hopkins Community Physicians (JHCP).\n* Access to smart phone or tablet to use app.\n\nExclusion Criteria:\n\n* Have diagnosis of CVD,\n* Stage 4-5 CKD, kidney failure, or on dialysis\n* Have a serious medical condition such as cancer;\n* On or planning to start Glucagon-like peptide-1 (GLP-1) receptor agonists in next 6 months;\n* Have cognitive impairment;\n* Are currently involved in other programs on improving LE8; or\n* Unwillingness to provide informed consent\n* Unable to speak, read, or communicate in English.","ALL","30 Years","79 Years",{"count":22,"type":23},94,"ESTIMATED","INTERVENTIONAL",[26],"EARLY_PHASE1","The investigators are proposing a new team-based shared decision-making (SDM) program. The goal of this study is to see whether this program is practical and whether it may help adults with cardiometabolic risk factors and cardiovascular-kidney-metabolic syndrome. The investigators will enroll adults from a primary care clinic in Maryland. People in the intervention group will take part in the 6-month program in addition to usual care. People in the control group will receive usual care only.",[29,30,31,32,33,34,35],"Hypertension (HTN)","Diabetes (DM)","Hyperlipidaemia","Kidney Disease","Obesity","Cardiovascular-kidney-metabolic (CKM)","Overweight",[37,38,39,40],"shared decision-making","Cardiovascular-kidney-metabolic","Behavioral counseling","Team-based care","NOT_YET_RECRUITING","2026-07-10",{"date":44,"type":45},"2026-07-13","ACTUAL",{"date":47,"type":23},"2026-08-10",{"date":49,"type":23},"2028-06-30",{"name":51,"class":52},"Johns Hopkins University","OTHER",{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100634702","phase-2-an-open-label-extension-safety-and-efficacy-study-of-qcz484-in-hypertensive-patients-100634702","NCT07543120","An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.","A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients.","Inclusion Criteria:\n\n1. Signed informed consent must be obtained prior to participation in the study.\n2. Successful completion of treatment period on QCZ484 study medication in parent study.\n3. No significant safety issue that may place participant at safety risk as determined by the Investigator.\n\nExclusion Criteria:\n\nParticipants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study:\n\n1. Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator.\n2. Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study.\n3. Permanent or persistent atrial fibrillation developed during the parent study.\n4. Clinically significant valvular heart disease developed during the parent study.\n5. Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","18 Years",{"count":62,"type":23},323,[64],"PHASE2","The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.",[29],[68,69,70],"Hypertension","open-label extension study","QCZ484","RECRUITING","2026-06-29",{"date":74,"type":45},"2026-07-01",{"date":76,"type":45},"2026-05-07",{"date":78,"type":23},"2031-11-30",{"name":80,"class":81},"Novartis Pharmaceuticals","INDUSTRY",13,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":18,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100645344","project-hope-hypertension-outreach-through-partnership-and-engagement-100645344","NCT07681726","Project HOPE (Hypertension Outreach Through Partnership and Engagement)","HOPE","Patient Participant Inclusion Criteria:\n\n* Adults aged ≥25 years\n* Stage 2 hypertension defined as either:\n\n  * Systolic Blood Pressure (SBP) ≥160 mmHg at screening (Group A); OR\n  * SBP 140-159 mmHg at screening with either documented elevation on more than one visit or a known history of hypertension (e.g., prior clinician diagnosis or current use of antihypertensive medication) (Group B)\n\nPatient Participant Exclusion Criteria:\n\n* \\\u003C25 years of age\n* Hypertensive emergency with SBP ≥180 mmHg at screening (these patients will be referred to the nearest health center per local protocol; they may be re-screened for eligibility at a subsequent visit if SBP meets the inclusion criteria above)\n* Diagnosis of end-stage renal disease (ESRD)\n* Condition which interferes with outcome measurement (e.g., dialysis)\n* Serious medical condition which either limits life expectancy or requires active management (e.g., certain cancers)\n* Cognitive impairment or other condition preventing participation in the intervention\n* Active alcohol or substance use disorder (i.e., not sober\u002Fabstinent for ≥30 days), screened using the NIAAA Single Alcohol Screening Question\n* Pregnant or planning pregnancy in the next 24 months\n* Currently nursing a child\n* Current participation in another research study focused on reducing blood pressure\n* Current participation in a care management program related to health conditions (e.g., weight reduction, smoking cessation)\n* Planning to move out of the geographic area within 7 months\n* Unwillingness to provide informed consent\n\nCommunity Health Nurse (CHN) Participant Inclusion Criteria:\n\n* CHNs who were directly involved in delivering the nurse-led community-based hypertension intervention\n* Willing to provide oral informed consent for participation in pre\u002Fpost-training surveys and semi-structured interviews\n\nCommunity Health Nurse (CHN) Participant Exclusion Criteria:\n\n* CHNs who were not directly involved in the delivery of the intervention","25 Years",{"count":92,"type":23},150,"OBSERVATIONAL","The goal of this study is to learn if a nurse-led, task-shifting, community-based program can help lower blood pressure in adults aged 25 and older with uncontrolled high blood pressure (hypertension) in Monrovia, Liberia. The program is delivered through community-based mobile clinics by community health nurses (CHNs) trained in WHO-aligned hypertension care within the Ministry of Health's (MOH) Community Health hypertension management protocols.\n\nParticipants will:\n\n* Receive blood pressure treatment from trained community health nurses (CHNs) at community-based mobile clinics in their communities, including medication and lifestyle counseling.\n* Complete surveys at their first visit, at 4 to 6 weeks, and at 3 months about their experience, satisfaction, and medication use.\n* Attend follow-up visits at the mobile clinic based on their blood pressure levels.\n\nCommunity health nurses delivering the program will complete structured training and be invited to complete surveys before and after training, and to take part in interviews about their experience at the end of the study.\n\nThe study will take place over 7 months in five high-thoroughfare communities in Monrovia, Liberia, and aims to enroll 150 participants.",[29],[68,97,98,99,100,101,102,103],"Blood Pressure","Nurse-Led Intervention","Task Shifting","Community Health Nurses","Liberia","Mobile Clinic","Low-Resource Settings","2026-06-26",{"date":106,"type":45},"2026-07-02",{"date":108,"type":23},"2026-09-01",{"date":110,"type":23},"2027-04-30",{"name":51,"class":52},1,{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100645175","finerenone-and-empagliflozin-combination-in-obesity-with-hypertension-a-12-week-prospective-parallel-design-double-blind-randomized-placebo-controlled-trial-100645175","NCT07678151","Finerenone and Empagliflozin Combination in Obesity With Hypertension: A 12-Week Prospective, Parallel-design, Double-blind, Randomized, Placebo-controlled Trial","Inclusion Criteria:\n\nAge ≥ 40 years.\n\nBody mass index (BMI) ≥ 28 kg\u002Fm² or abdominal obesity, defined as meeting any of the following:\n\nWaist circumference ≥ 90 cm (male) or ≥ 85 cm (female); Waist-to-hip ratio ≥ 0.9 (male) or ≥ 0.85 (female); Waist-to-height ratio ≥ 0.5. Unattended office systolic blood pressure (SBP) ≥ 140 mmHg and \\\u003C 160 mmHg during the screening period (within 1 week before randomization).\n\nCurrently taking no more than 2 antihypertensive agents (fixed-dose combinations are counted by the number of active ingredients).\n\nNo changes in the type or dose of antihypertensive medications within 4 weeks before the screening visit.\n\nProvide written informed consent.\n\nExclusion Criteria:\n\nDiastolic blood pressure ≥ 100 mmHg. Diagnosed diabetes mellitus or fasting plasma glucose ≥ 7.0 mmol\u002FL. History of heart failure (any ejection fraction) or left ventricular ejection fraction \\\u003C 50%.\n\nAcute coronary syndrome, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) within 90 days.\n\nStroke or transient ischemic attack (TIA) within 90 days. Known secondary hypertension (e.g., bilateral renal artery stenosis \\>75%, aldosteronism, pheochromocytoma), except documented sleep apnea.\n\nSevere hepatic dysfunction (AST\u002FALT \\> 3× upper limit of normal, or Child-Pugh class C).\n\nAcute kidney injury within 6 months before screening, or eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m², or kidney transplant (or planned).\n\nPrimary adrenal insufficiency (Addison's disease). Contraindications to any component of the study drugs (e.g., urinary tract infection within 90 days, serum potassium \\> 5.0 mmol\u002FL, drug allergy).\n\nMajor surgery under general anesthesia within 90 days before screening, or elective surgery planned within 90 days after screening.\n\nGastrointestinal surgery or disease that, in the investigator's judgment, may affect absorption of the study drug.\n\nPregnancy, lactation, or planned pregnancy (for both male and female participants) during the study period.\n\nActive malignancy. Life expectancy \\\u003C 3 months. Use of strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampicin, carbamazepine, phenytoin) that cannot be discontinued within 7 days before Day 1.\n\nUse of mineralocorticoid receptor antagonists (e.g., finerenone, eplerenone, spironolactone), renin inhibitors, SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), or SGLT-1\u002F2 inhibitors (e.g., canagliflozin) within 8 weeks before screening or during the intervention period.\n\nUse of potassium supplements, potassium-sparing diuretics (e.g., amiloride, triamterene), or potassium-binding agents within 8 weeks before screening or during the intervention period.\n\nParticipation in a clinical trial of empagliflozin or finerenone within 1 month before screening.\n\nCurrent use of weight-loss medications (e.g., GLP-1 receptor agonists, GIP\u002FGLP-1 dual agonists, GLP-1\u002FGCGR dual agonists) or prior\u002Fplanned bariatric surgery.\n\nKnown or suspected orthostatic hypotension or autonomic dysfunction. Any condition that, in the investigator's opinion, makes the participant unsuitable for the study.","40 Years",{"count":121,"type":23},260,[123],"NA","The EFFORT Study (Empagliflozin and Finerenone Combination in Obesity with Hypertension) is a 12-week, randomized, double-blind, placebo-controlled trial that aims to test whether combining empagliflozin (10 mg\u002Fday) with finerenone (10 mg\u002Fday, up-titrated to 20 mg after 4 weeks) can significantly lower office systolic blood pressure in adults with obesity and stage 1 hypertension (systolic BP 140-160 mmHg) who are on up to two stable antihypertensives. The study will enroll 260 participants from community settings. Beyond blood pressure, the trial will also assess effects on diastolic pressure, cumulative BP exposure, urinary albumin-to-creatinine ratio, inflammation (hs-CRP), fasting glucose, body weight, and quality of life. Safety monitoring focuses on hyperkalemia, acute kidney injury, hypotension, and hypoglycemia. If positive, this research may offer a new, mechanism-based therapeutic strategy for the growing population with cardiometabolic risk, potentially providing better cardiovascular and kidney protection than conventional approaches.",[29],[127,128,97,33],"Sodium-Glucose Transporter 2 Inhibitors","Mineralocorticoid Receptor Antagonists","2026-06-25",{"date":74,"type":45},{"date":44,"type":23},{"date":133,"type":23},"2027-08-31",{"name":135,"class":52},"Heart Health Research Center",2,{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":144,"targetDuration":146,"studyType":93,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":153,"leadSponsor":155,"locationsCount":136},"100639457","impact-htn-study-of-patients-with-hypertension-100639457","NCT07579260","IMPACT-HTN Study of Patients With Hypertension","Prospective Early Patient Experience Initiative (IMPACT-HTN)","Inclusion Criteria:\n\n* Signed and dated informed consent form\n* Ability to answer survey questions and to report blood pressure reading monthly\n* Male and female participants; 18 years or older\n* Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit\n* Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg\n\nExclusion Criteria:\n\n* Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and\u002For Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg\n* Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator\n* Heart failure NYHA functional class III and IV or NT-proBNP \\> 500 pg\u002FmL\n* Severe renal insufficiency or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2\n* Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\\> 3 x ULN)",{"count":145,"type":23},100,"97 Days","An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.",[29,68,149],"Blood Pressure, High","2026-06-24",{"date":72,"type":45},{"date":74,"type":23},{"date":154,"type":23},"2027-04-01",{"name":156,"class":52},"Vivek Bhalla",{"id":158,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":160,"briefSummary":27,"conditions":161,"keywords":162,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":167,"locationsCount":4},"100643950",{"count":22,"type":23},[26],[29,30,31,32,33,34,35],[37,38,39,40],"2026-06-22",{"date":129,"type":45},{"date":74,"type":23},{"date":49,"type":23},{"name":51,"class":52},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":175,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":112},"100643819","investigating-vascular-properties-of-hemi-and-spg-signals-in-individuals-with-or-at-risk-for-chronic-kidney-disease-100643819","NCT07604922","Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease","STIMULUS-CKD","Inclusion Criteria:\n\n* Common Inclusion Criteria:\n\n  * Adults aged over 18 years, of both sexes\n  * Patients eligible for or affiliated with a social security scheme\n  * Patients who have provided written informed consent to participate in the study\n\nCommon Exclusion Criteria:\n\n* Inability to give informed consent\n* Persons under legal protection (guardianship, trusteeship, or court protection)\n* Language barrier or psychological refusal to read the information\n* Medical conditions with a life expectancy \\\u003C 1 year according to clinical judgment\n* Ongoing participation restriction due to another clinical research study\n* Pregnant women (due to physiological hemodynamic changes in blood pressure and arterial stiffness during pregnancy)\n* Cardiac arrhythmias: current atrial fibrillation or high-degree atrioventricular block\n\nExclusion Criteria:\n\n* Hypertension Group\n\n  * Inclusion: Prior diagnosis of arterial hypertension\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol\n    * Type 2 diabetes Type 2 Diabetes Group\n  * Inclusion:\n  * Prior diagnosis of type 2 diabetes\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n\n    * CKD with GFR \\\u003C 60 mL\u002Fmin\n    * ACR \\> 30 mg\u002Fmmol Moderate CKD Group\n  * Inclusion:\n  * Moderate CKD (eGFR between 30 and 60 mL\u002Fmin) (CKD-EPI)\n  * Patients scheduled for arterial stiffness assessment as part of routine care\n  * Stable cardiovascular treatment in the previous 1 month\n  * Exclusion:\n  * No specific exclusion criteria beyond common exclusions Severe CKD Group\n  * Inclusion:\n\n    * Severe CKD (GFR \\\u003C 30 mL\u002Fmin for ≥ 2 months)\n    * Patients scheduled for arterial stiffness assessment as part of routine care\n    * Stable cardiovascular treatment the previous 1 month\n  * Exclusion: No specific exclusion criteria beyond common exclusions20 \u002F 48 C25-07\\_Protocole\\_ V1.0\\_01.12.2025 Healthy Volunteers Group\n  * Inclusion: No documented chronic disease\n  * Exclusion:\n\n    * Moderate or severe CKD (GFR \\\u003C 60 mL\u002Fmin) (CKD-EPI)\n    * Hypertension\n    * Type 2 diabetes\n    * Stable cardiovascular treatment in the previous 1 month",true,{"count":177,"type":23},165,[123],"This prospective, single-center clinical investigation conducted in France will evaluate two non-invasive investigational devices (HEMI and SPG-NINOX) designed to assess microcirculation in adults. The study will include 165 participants divided into five groups (33 per group): healthy volunteers, patients with hypertension without chronic kidney disease (CKD), patients with type 2 diabetes without CKD, patients with moderate CKD, and patients with severe CKD. The primary objective is to compare baseline small vessel pressure measured with the HEMI (Multi-spectral optical system for microcirculation hemodynamics) device across groups in order to identify microvascular alterations associated with cardiometabolic and renal disease. Secondary objectives include assessment of microvascular responses after post-ischemic hyperemia, evaluation of SPG-derived (Speckle plethysmography) small vessel flow and volume parameters, comparison with reference vascular measurements (including SphygmoCor and ultra-high frequency ultrasound), and evaluation of feasibility, acceptability, and measurement reproducibility. Participation is non-randomized, based on participants' pre-existing clinical condition, and study procedures are non-invasive with an expected visit duration of approximately 60 minutes.",[181,29,182],"Chronic Kidney Disease","Type 2 Diabetes Mellitus (T2DM)","2026-06-04",{"date":185,"type":45},"2026-06-08",{"date":187,"type":23},"2026-06-15",{"date":189,"type":23},"2028-09-15",{"name":191,"class":192},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":200,"minAge":60,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":24,"phases":203,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":213,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":112},"100643173","mobile-health-program-for-post-preeclampsia-hypertension-100643173","NCT07599579","Mobile Health Program for Post-Preeclampsia Hypertension","Multilevel Mobile Health Program to Improve Hypertension Among Midlife Women After Hypertensive Disorder of Pregnancy","Inclusion Criteria:\n\n* Women who had a history of HDP (either gestational HTN or preeclampsia) diagnosed by ACOG guidelines at the time of delivery at Magee-Womens Hospital between 2008 and 2015, thus 10 to 20 years from their index pregnancy complicated by HDP.\n* Evidence of current stage 2 HTN (BP ≥ 140\u002F90 mmHg with or without treatment with antihypertensive medication).\n\nExclusion Criteria:\n\n* Known clinical CVD (prior myocardial infarction, stroke, heart failure, or peripheral arterial disease).\n* Males will also be excluded from this study as it focuses on pregnancy related conditions.\n* Children will be excluded as the study is only recruiting people who are 10-20 years postpartum.","FEMALE",{"count":202,"type":23},50,[123],"Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.",[29,206,207],"Preeclampsia","Hypertensive Disorders of Pregnancy (HDP)",[209,210,211,212],"hypertension","preeclampsia","coaching","home blood pressure monitoring",{"date":185,"type":45},{"date":215,"type":23},"2026-06",{"date":217,"type":23},"2027-10",{"name":219,"class":52},"University of Pittsburgh",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":229,"conditions":230,"keywords":235,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":112},"100637379","impact-of-online-medical-misinformation-100637379","NCT07601308","Impact of Online Medical Misinformation","Impact of Online Medical Misinformation on Medication Adherence, Treatment Decisions, and Health-Seeking Behavior Among Patients With Chronic Diseases","Inclusion Criteria:\n\n* Adults ≥ 18 years\n* Disease duration ≥ 6 months\n* Social media use at least once weekly\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Severe cognitive or psychiatric disorders",{"count":228,"type":23},300,"This mixed-methods study aims to examine the impact of exposure to online medical misinformation on medication adherence, treatment decision-making, and healthcare-seeking behavior among patients with chronic diseases. The study targets patients with hypertension, diabetes mellitus, and dyslipidemia and evaluates how misinformation influences real-world health behaviors. Quantitative and qualitative data will be collected concurrently to provide a comprehensive understanding of misinformation-related health risks.",[231,232,233,234,30,29],"Medical Misinformation","Medication Adherence","Health-Seeking Behavior","Chronic Diseases",[236,237,232],"Online Misinformation","Chronic Disease",{"date":239,"type":45},"2026-06-05",{"date":241,"type":23},"2026-05-15",{"date":243,"type":23},"2026-06-30",{"name":245,"class":52},"Alexandria University",{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":24,"phases":255,"briefSummary":256,"conditions":257,"keywords":260,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":267,"leadSponsor":269,"locationsCount":112},"100621855","rush-food-is-medicine-veggie-rx---gusnip-produce-prescription-100621855","NCT07376044","RUSH Food is Medicine Veggie Rx - GusNIP Produce Prescription","GusNIP Produce Prescription Project","Inclusion Criteria:\n\n* Adults over 18 years of age\n* Participants receiving medical care at Rush\n* Participants with a diagnosis of hypertension and\u002For diabetes\n* Participants with a positive screen for food insecurity\n* Participants eligible for medical assistance through a state plan\n* Participants eligible for benefits through the SNAP program\n* Participants are member of a low-income household\n* Participants willing to participate for duration of the program (12-months)\n* Participants residing in service area of the referring Rush clinic\n\nExclusion Criteria:\n\n* Adults unable to consent\n* Individuals not yet adults - infants, children, teenagers\n* Incarcerated individuals",{"count":254,"type":23},400,[123],"The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and\u002For diabetes. The main questions it aims to answer are:\n\n* Does participation increase fruit and vegetable consumption for participants?\n* Does participation reduce individual and household food insecurity?\n* Does participation reduce healthcare utilization and associated costs?\n* Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)?\n* Does participation support the local economy by increasing participant spending at local food vendors?\n\nParticipants will:\n\n* Receive 6 months home delivered produce prescription boxes\n* Receive 6 months match of produce vouchers\n* Receive nutrition education and participate in Chronic Disease Self-Management classes",[258,259,29],"Food Insecurity","Diabetes in Adults",[258,261,262,263,264],"Food is Medicine","Nutrition Security","Diet-related Chronic Disease","Produce Prescription",{"date":239,"type":45},{"date":243,"type":23},{"date":268,"type":23},"2028-09",{"name":270,"class":52},"Rush University Medical Center",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":24,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":288,"leadSponsor":290,"locationsCount":112},"100638306","dual-language-b-more-for-hypertension-100638306","NCT07623031","Dual-Language B-MORE for Hypertension","B-MORE for Hypertension","Inclusion Criteria:\n\n* Age ≥18\n* Having self-reported hypertension (BP ≥ 140\u002F90)\n* Understanding English or Spanish instructions fluently\n\nExclusion Criteria:\n\n* Known or planned pregnancy in the next 3 months assessed via self-report\n* Cognitive impairment preventing completion of study procedures.\n* Have previous, formal mindfulness training (e.g., MBSR)\n* Other unstable illness judged by medical staff to interfere with study involvement.",{"count":279,"type":23},20,[123],"This pilot study is a single-arm clinical feasibility trial evaluating the feasibility, acceptability, and preliminary efficacy of a brief adaptation of Mindfulness-Oriented Recovery Enhancement (B-MORE) for reducing stress and high blood pressure in hypertensive English- and Spanish-speaking patients (n=20). The intervention, a 2-hour online training in stress management and hypertension, will be delivered virtually in a small-group format over two 60-minute sessions.",[29,283],"Chronic Stress","2026-06-01",{"date":286,"type":45},"2026-06-03",{"date":215,"type":23},{"date":289,"type":23},"2026-12",{"name":291,"class":52},"Florida State University",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":24,"phases":302,"briefSummary":303,"conditions":304,"keywords":307,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":322},"100611457","accuracy-of-a-cuffless-photoplethysmography-ppg-chest-patch-monitor-for-24-hour-ambulatory-blood-pressure-monitoring-abpm-100611457","NCT07240831","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring (ABPM)","Accuracy of a Cuffless Photoplethysmography (PPG) Chest-Patch Monitor for 24-hour Ambulatory Blood Pressure Monitoring","PPG ABPM","Inclusion Criteria\n\n* Females and Males subjects 18 years or older (from all skin tones\u002Fcolors)\n* Scheduled for ABPM for hypertension screening, evaluation, or management\n* Subjects capable of using an application temporarily downloaded (for the duration of the study) on a personal smart phone device or on a device provided by the study sponsor\n* Subjects with Atrial fibrillation or Atrial flutter are eligible to participate if standard cuff-based ABPM monitor can capture blood pressure at initialization\n\nExclusion Criteria\n\n* Indication for ABPM is orthostatic hypotension or Postural Orthostatic Tachycardiac Syndrome as indicated on the ABPM referral order\n* Any neurological, psychological, or other condition impairing the ability to provide informed consent or participate in the study\n* Inability to reliably access the Internet via a smart phone\n* Not able to perform standard cuff-based ABPM\n* Average absolute difference between the two arms is greater than 15 mmHg for Systolic Blood Pressure (SBP) or greater than 10 mmHg Diastolic Blood Pressure (DBP) during the initialization\u002Fcalibration phase\n* Subjects with known allergy to adhesives or skin patches\n* Subjects with solid dark tattoos on the area where the PPG-based device is attached\n* Subjects who are unwilling to have their chest hair shaved, if needed, to install the device (the device uses adhesives and needs to be in direct contact with the skin without hair)\n* Subjects who are unwilling to comply with the study instructions (avoid vigorous exercise and showering for 24 hours while the device is in place)",{"count":301,"type":23},600,[123],"This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake\u002FAsleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.",[97,305,29,306],"Heart Disease","Blood Pressure Monitoring",[308,309,29,310,311,312,313],"BLOOD PRESSURE","BLOOD PRESSURE MONITORING","CUFFLESS PHOTOPLETHYSMOGRAPHY","PPG","CUFFLESS","vital signs",{"date":315,"type":45},"2026-06-02",{"date":317,"type":45},"2025-12-15",{"date":319,"type":23},"2026-10-30",{"name":321,"class":81},"Biobeat Technologies Ltd.",10,{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":175,"sex":200,"minAge":60,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":335,"conditions":336,"keywords":339,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":112},"100640915","effect-of-isometric-handgrip-exercise-on-blood-pressure-in-pregnant-women-100640915","NCT07607795","Effect of Isometric Handgrip Exercise on Blood Pressure in Pregnant Women","Effect of Isometric Handgrip Exercise on Cardiovascular and Cognitive Responses in Normotensive and Hypertensive Pregnant Women (GRIP4HEALTH)","GRIP4HEALTH","Inclusion Criteria:\n\n* Pregnant women covered by the French National Health Insurance system\n* Pregnant women who do not object to participation in the study\n* Women belonging to one of the following two groups:\n* Women with chronic hypertension present before pregnancy (diagnosed within the past 5 years), defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg, without antihypertensive treatment\n* Normotensive pregnant women, defined as systolic blood pressure (SBP) \\\u003C 140 mmHg and diastolic blood pressure (DBP) \\\u003C 90 mmHg before pregnancy\n\nExclusion Criteria:\n\n* Current treatment for chronic or gestational hypertension\n* Known cardiovascular disease other than chronic hypertension\n* Age under 18 years\n* Persons deprived of liberty\n* Inability to speak or adequately understand French\n* Persons hospitalized without consent who are not subject to legal protection measures, and persons admitted to a health or social institution for purposes other than research\n* Persons currently excluded from participation in another research study\n* Persons under judicial protection or guardianship Type 1 or type 2 diabetes\n* Severe or extreme obesity (BMI ≥ 40 kg\u002Fm²)\n* Thyroid disease\n* Heavy smoking","45 Years",{"count":333,"type":23},30,[123],"Hypertension during pregnancy is a major public health concern, increasing the risk of cardiovascular complications for both the mother and the fetus. Women with chronic hypertension are at higher risk of adverse outcomes, and elevated blood pressure during pregnancy has also been associated with long-term cardiovascular and cognitive impairments.Regular physical activity is recognized as an effective non-pharmacological strategy to reduce blood pressure. Among different exercise modalities, isometric exercise has shown promising effects in lowering blood pressure in the general population, with minimal cardiovascular strain. However, its effects and safety in pregnant women, particularly those with hypertension, remain poorly understood.In addition to cardiovascular alterations, hypertension during pregnancy may also impact cognitive function, potentially through changes in cerebral perfusion and vascular function. Despite these associations, the combined cardiovascular and cognitive responses to exercise in this population have not been fully explored.This study aims to investigate the effects of isometric handgrip exercise on cardiovascular and cognitive responses in pregnant women with and without chronic hypertension, in order to better understand its potential as a safe and effective non-pharmacological intervention during pregnancy.",[337,338,29],"Pregnancy","Pregnancy - Prenatal Testing",[340,341,97,342,337,68,343,344],"Isometric Exercise","Handgrip Exercise","Ambulatory Blood Pressure Monitoring","Arterial Stiffness","Cognitive Function","2026-05-21",{"date":347,"type":45},"2026-05-26",{"date":349,"type":45},"2026-03-06",{"date":351,"type":23},"2027-09-30",{"name":353,"class":52},"University of Poitiers",{"id":355,"slug":356,"hasResults":12,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":4,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":361,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":24,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":390,"leadSponsor":392,"locationsCount":394},"100634834","navigating-hypertension-and-food-insecurity-100634834","NCT07544836","Navigating Hypertension and Food Insecurity","Navigating Hypertension and Food Insecurity: A Produce Prescription Program to Improve Health Outcomes for Native Hawaiian and Pacific Islander Communities","Inclusion Criteria:\n\n* patient of the participating health center clinic\n* age 20 years and older\n* positive screen for food insecurity using a validated two-question tool\n* physician diagnosed HTN and continued indications of SBP \\>130 mmHG\n\nExclusion Criteria:\n\n* prior history of cardiovascular disease\n* unable to provide informed consent and complete study procedures in English","20 Years",{"count":363,"type":23},250,[123],"This multi-site randomized controlled trial uses a community-based approach to evaluate a Food as Medicine program for Native Hawaiian and Pacific Islander (NHPI) adults in Hawaii who have high blood pressure and difficulty affording healthy food. The study has two main goals: (1) to implement a produce prescription program and see if adding personal support from Community Health Workers (CHW) improves blood pressure among other health outcomes, and (2) to determine the program's cost-effectiveness.\n\nThe study will take place across three Federally Qualified Health Centers in Hawaii. Produce prescription program participants at each site will receive $100 per month, either in the form of produce boxes or monthly vouchers to purchase fruits and vegetables, for 12 months (totaling $1200). In past studies, personal challenges (e.g., lack of transportation, lack of cooking skills) have made it difficult for participants to use the vouchers and\u002For the purchased produce. In other food as medicine interventions, participants have similarly faced various personal, social, and environmental barriers that limit the program's efficacy. To help participants navigate through these challenges, the investigators want to test adding 1-on-1 support from a CHW throughout the program. Other studies have found that health interventions delivered by CHWs have been effective in reducing blood pressure, blood glucose and weight, especially among vulnerable populations, such as NHPIs and those with food insecurity. The CHWs in this study will receive a training using a curriculum tailored specifically to their community and that is in alignment with the Pilinahā: The Four Connections Framework, which focuses on key connections that Indigenous people seek to attain health and can be employed to overcome health disparities.\n\nTo test the effectiveness of the added CHW support, there will be two groups of participants:\n\nGroup 1 (Intervention) will receive the monthly produce prescription ($100 vouchers or produce box) plus meet with a CHW every two months for support with program challenges.\n\nGroup 2 (Control) will receive the same monthly produce prescription, but will not have meetings with a CHW.\n\nThe investigators want to see if the added support from CHWs leads to better blood pressure results, among other health outcomes.\n\nUpon providing informed consent and enrolling into the program, produce prescription program participants will:\n\n* Attend 5 study visits over the one year program. These happen at the start, and then at 3, 6, 9, and 12 months.\n* Complete health checks at the first visit. This includes getting a home blood pressure monitor and learning about heart health and nutrition. Staff will measure height, weight, waist size, and blood pressure.\n* Answer surveys about their demographic background, health habits, diet, and culture.\n* Receive $100 in vouchers every month for 12 months to redeem for fruits and vegetables at a local retailer.\n* Group 1 will additionally meet with a CHW every two months for 1-on-1 support with any challenges related to the program.\n* Group 2 will receive monthly reminders to use their vouchers but no CHW meetings.\n\nAfter the program ends, researchers will analyze the financial value of the intervention. This involves calculating the total cost to run the program (including vouchers, CHW training and salaries, and administrative costs) and comparing it to potential savings in healthcare costs. By looking at improvements in blood pressure, researchers can estimate how many heart-related health problems were prevented and how much money was saved on medical care.",[29,258],[209,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385],"high blood pressure","produce prescription","food insecurity","cardiovascular disease prevention","community health worker","fruit and vegetable vouchers","Randomized Controlled Trial","Community-Based Participatory Research","Social Determinants of Health","cost-effectiveness analysis","Native Hawaiian health","Pacific Islander health","Federally Qualified Health Center","Food as Medicine","Hypertension self-management support","cost-effectiveness","healthcare cost reduction analysis","quality-adjusted life year","2026-05-18",{"date":388,"type":45},"2026-05-20",{"date":108,"type":23},{"date":391,"type":23},"2028-03",{"name":393,"class":52},"University of Hawaii",3,{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":24,"phases":403,"briefSummary":404,"conditions":405,"keywords":408,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":136},"100639489","clinical-feasibility-of-cardiac-neuromodulation-therapy-for-heart-failure-with-preserved-ejection-fraction-100639489","NCT07598760","Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction","Clinical Feasibility of Cardiac Neuromodulation Therapy (CNT) as Treatment for HFpEF","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical indication for dual-chamber pacemaker implantation or replacement\n* Diagnosis of heart failure with preserved ejection fraction (HFpEF), defined as left ventricular ejection fraction ≥50%\n* History of hypertension\n* NYHA functional class II or III\n* On stable guideline-directed medical therapy\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* NYHA class IV heart failure\n* Permanent or persistent atrial fibrillation\n* Recent acute decompensated heart failure\n* Significant valvular heart disease requiring intervention\n* Severe comorbid conditions that, in the investigator's judgment, would make study participation unsafe\n* Pregnant or breastfeeding individuals",{"count":279,"type":23},[123],"This is an open-label pilot study to evaluate the feasibility of Cardiac Neuromodulation Therapy (CNT) in patients with high blood pressure and heart failure who require dual-chamber pacemaker implantation or replacement. The study will assess blood pressure and heart function at rest and during exercise, with and without CNT, for up to 12 months. Participants will receive the Moderato Plus device and complete scheduled follow-up visits. After study completion, CNT therapy will be discontinued and participants will return to standard medical care.",[29,406,407],"Heart Failure With Preserved Ejection Fraction (HFpEF","Hypertension, Systolic",[409,410,68],"CNT","HFpEF","2026-05-14",{"date":388,"type":45},{"date":414,"type":23},"2026-05-30",{"date":416,"type":23},"2028-11-30",{"name":418,"class":81},"BackBeat Medical Inc",{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":175,"sex":18,"minAge":60,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":112},"100638605","low-energy-availability-and-hypertension-in-division-i-hbcu-athletes-100638605","NCT07583940","Low Energy Availability and Hypertension in Division I HBCU Athletes","Cardiovascular Outcomes and Relative Energy Deficiency in Division I HBCU Athletes: CORE-DI Study","CORE-DI","Inclusion Criteria:\n\nAge: 18-25yrs Sex: Male and Female Training Status\u002FExperience: HBCU Division I collegiate athletes with \\>3yrs of previous competitive experience\n\nExclusion Criteria:\n\n* Persons who self-report any known disease, or unknown issue precluding collegiate competitive participation: Excluded\n* Those who have any orthopedic injuries, concussions, or conditions which would preclude safe testing: Excluded\n* Individuals who are not yet adults \\\u003C18yrs (e.g.: infants, children, teenagers):\n\nExcluded\n\n* Persons who have a pacemaker: Excluded\n* Persons who are pregnant: Excluded","26 Years",{"count":92,"type":23},"Low energy availability (LEA) occurs when the body does not get enough calories to support both daily life and exercise. This can happen when athletes train hard but do not eat enough to match their energy needs. In both 2012 and 2023, the International Olympic Committee on Sports Nutrition recognized LEA as an important factor that can increase the risk of cardiometabolic disease (CMD), which includes conditions like high blood pressure, diabetes, and heart disease. LEA can affect many systems in the body. It may disrupt hormones (such as menstrual cycles), cause changes in blood sugar and cholesterol levels, weaken bones, impair digestion, and negatively impact mental health. Over time, these changes may be linked to chronic inflammation, which plays a key role in the development of disease. Maintaining proper energy balance can be especially challenging for athletes because they often train at levels well above general health recommendations. As a result, even highly fit athletes may unintentionally remain in a calorie deficit. Our recent pilot research found a significant relationship between LEA and high blood pressure in Black Division I collegiate athletes. This is important because this group has historically been understudied and may face a higher risk of serious heart-related events, including sudden cardiac death. Despite assumptions that collegiate athletes are uniformly healthy, there is a need to better understand hidden health risks in this population. Our research aims to improve how we identify and monitor early signs of cardiometabolic disease by examining markers such as inflammation, blood sugar, and cholesterol levels. These insights will help healthcare providers, athletes, and families make more informed decisions about nutrition, training, and long-term health. Ultimately, this work seeks to develop practical, evidence-based strategies to protect athlete health and reduce the risk of serious cardiovascular outcomes.",[431,29,432],"Vascular Stiffness","Nutritional Deficiency Related Cardiovascular Risk in Athletes",[434,209,435,436,437,438],"vascular stiffness,","nutritional deficiency","energy balance","RED-S","SDOH","2026-05-06",{"date":441,"type":45},"2026-05-13",{"date":443,"type":45},"2026-01-06",{"date":49,"type":23},{"name":446,"class":52},"North Carolina Agriculture & Technical State University",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":175,"sex":18,"minAge":60,"maxAge":454,"enrollmentInfo":455,"targetDuration":457,"studyType":93,"phases":4,"briefSummary":458,"conditions":459,"keywords":460,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":469,"leadSponsor":471,"locationsCount":112},"100639549","cohort-study-of-metabolic-disease-and-hypertension-100639549","NCT07577063","Cohort Study of Metabolic Disease and Hypertension","Metabolic Disease and Hypertension in Adults: A Prospective Cohort Study (Phase One)","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n* No prior diagnosis of type 2 diabetes mellitus or hypertension\n* Receiving care at primary health care units of the Mexican Social Security Institute (IMSS) or IMSS-Bienestar\n* Willing and able to provide informed consent\n* Willing to participate in baseline and annual follow-up assessments\n\nExclusion Criteria:\n\n* Prior diagnosis of type 2 diabetes mellitus or hypertension\n* Pregnancy at the time of enrollment\n* Any condition that limits the ability to perform study procedures, including the six-minute walk test\n* Any condition that, in the opinion of the investigators, may interfere with participation or follow-up","65 Years",{"count":456,"type":23},2500,"5 Years","The goal of this observational study is to learn how type 2 diabetes and high blood pressure develop over time in adults in Mexico. The study will include men and women between 18 and 65 years of age who do not have a previous diagnosis of these conditions.\n\nThe main questions this study aims to answer are:\n\nWhat factors increase the risk of developing type 2 diabetes? What factors increase the risk of developing high blood pressure?\n\nParticipants will not receive any experimental treatment. Researchers will observe their health as part of their regular medical care.\n\nParticipants will:\n\nAttend an initial visit that includes physical measurements, blood tests, and questionnaires about their health, lifestyle, and environment Perform a simple walking test to measure physical fitness Return once a year for follow-up visits over a period of five years\n\nDuring the study, researchers will monitor participants to identify new cases of type 2 diabetes and high blood pressure.\n\nThe results of this study may help improve prevention strategies and support public health programs aimed at reducing chronic diseases in Mexico.",[182,29],[461,68,462,33,463,464],"Type 2 Diabetes Mellitus","Cardiometabolic risk","Prediabetes","Prehypertension","2026-05-05",{"date":467,"type":45},"2026-05-11",{"date":215,"type":23},{"date":470,"type":23},"2031-12",{"name":472,"class":192},"Coordinación de Investigación en Salud, Mexico",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":175,"sex":18,"minAge":60,"maxAge":479,"enrollmentInfo":480,"targetDuration":4,"studyType":24,"phases":482,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":112},"100627816","the-effects-of-brief-periods-of-exercise-on-blood-pressure-100627816","NCT07453550","The Effects of Brief Periods of Exercise on Blood Pressure","Inclusion Criteria:\n\n* 18-55 yrs.\n* 24 hour average BP \\>110\u002F70 mmHg, but \\\u003C 160 systolic blood pressure\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Currently taking anti-hypertensive medication smokers and alcohol drinkers Inability to undertake exercise intervention (resistance and isometric exercise)\n\nCurrent medical history of any of the following:\n\nhyperaldosteronism Diabetes mellitus (Type 1 or type 2) Heart disease Stroke or transient ischemic attack Peripheral neuropathy Aortic aneurysm and\u002For peripheral arterial disease If female, pregnancy or currently breast feeding Enrolled in another Clinical Trial of an Interventional Medicinal Product or Medical Device or other interventional study Medical condition that, in the opinion of the investigator, would make the participant unsuitable for the study On long term warfarin Allergies to blood pressure cuff materials or ultrasound gel\n\nPrevious medication history of any of the following:\n\nhyperaldosteronism Heart disease Stroke or transient ischemic attack Peripheral neuropathy Aortic aneurysm and\u002For peripheral arterial disease thromboembolism Infection within limb within 3 months On long term warfarin Allergies to blood pressure cuff materials or ultrasound gel","55 Years",{"count":481,"type":23},45,[123],"High blood pressure is a common medical condition that affects the body's arteries. It's also called hypertension. Untreated hypertension increases the risk of heart attack, stroke and other serious health problems. Exercise is a promising tool in hypertension management. Regular participation in exercise improves vascular health, heart and lung function, and multisystem health. However, the direct evidence of the treatment effects of a brief period of exercise on blood pressure in individuals with hypertension is limited. A brief period of exercise refers to an exercise protocol that only lasts for a very short period of time, such as 5-10 minutes.",[29,485],"Pre Hypertension",[487],"isometric exericse","2026-04-27",{"date":490,"type":45},"2026-05-01",{"date":492,"type":45},"2026-02-01",{"date":494,"type":23},"2027-06",{"name":496,"class":52},"University of Hartford",{"id":498,"slug":499,"hasResults":12,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":200,"minAge":60,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":24,"phases":507,"briefSummary":508,"conditions":509,"keywords":510,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":515,"startDateStruct":517,"completionDateStruct":519,"leadSponsor":521,"locationsCount":112},"100628156","community-health-worker-coaching-to-reduce-cardiovascular-risk-among-women-after-a-hypertensive-disorder-of-pregnancy-100628156","NCT07457970","Community Health Worker Coaching to Reduce Cardiovascular Risk Among Women After a Hypertensive Disorder of Pregnancy","Community Health Worker Coaching to Reduce CVD Disease Risk Among Women After a Hypertensive Disorder of Pregnancy","HERHEART","Inclusion Criteria:\n\n* 28 weeks gestation\n* A current hypertensive disorders in pregnancy or chronic hypertension\n* Singletons\n* Access to phone\n* Plan to deliver at Prisma Health-Midlands Hospital.\n\nExclusion Criteria:\n\n* Multiples\n* Fetal anomaly\n* Don't speak English\n* Already delivered a baby greater than 14 days ago.",{"count":506,"type":23},240,[123],"The goal of this clinical trial is to find out whether an enhanced program works better than remote blood pressure monitoring (RBPM) alone for women who had high blood pressure during pregnancy. The enhanced program combines RBPM with a lifestyle program led by a community health worker (CHW).\n\nThe study will examine whether the enhanced program helps women better control their blood pressure, lowers their average resting blood pressure, improves heart health risk factors (such as weight, diet, physical activity), supports mental well-being, and reduces emergency department visits and hospital readmissions by 6 months after delivery.",[306,29,337],[372,511,512,513,514],"lifestyle intervention","Blood pressure monitoring","postpartum","Cardiovascular risk",{"date":516,"type":45},"2026-05-04",{"date":518,"type":45},"2026-04-24",{"date":520,"type":23},"2029-07-15",{"name":522,"class":52},"University of South Carolina",{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":545,"leadSponsor":547,"locationsCount":112},"100609716","clinical-decision-support-tool-for-the-treatment-of-uncontrolled-hypertension-100609716","NCT07218198","Clinical Decision Support Tool for the Treatment of Uncontrolled Hypertension","A Stepped Wedged, Cluster Randomized Clinical Trial to Evaluate the Efficacy of a Clinical Decision Support Tool in the Treatment of Uncontrolled Hypertension","AI-HTN","Inclusion Criteria:\n\n1. Men and women 18 years of age or older\n2. Electronic Health Record (EHR) of hypertension AND prescribed at least one BP lowering medication\n3. Office systolic BP of 130 mmHg or higher\n4. Willing and able to comply with the study instructions AND attend a scheduled study visit\n\nExclusion Criteria:\n\n1. Women who are pregnant, plan to become pregnant, or are breast-feeding\n2. Know heart failure with reduced ejection fraction and a left ventricular ejection fraction of less than 40%\n3. End-stage kidney disease currently undergoing renal replacement therapy, or an eGFR \\\u003C 15ml\u002Fmin\u002F1.73m2\n4. In the opinion of the investigator, any other condition that will preclude participation in the study",{"count":532,"type":23},168,[123],"The goal of this clinical trial is to study whether having a clinical decision support (CDS) tool available to clinician use will more effectively lower BP 4 weeks after an outpatient visit compared with usual care. The main objective is to assess the impact of the CDS tool, that is embedded with the electronic medical record (EMR), that is available during outpatient clinical encounters, on blood pressure (BP) changes among participants with uncontrolled hypertension.\n\nParticipants will:\n\nVisit the clinic 4 weeks, after their initial clinician visit, for a BP check.",[68,29,149,536],"Blood Pressure Control",[538,68,97,539,540,541],"Uncontrolled Hypertension","High Blood Pressure","Artificial Intelligence","AI",{"date":543,"type":45},"2026-04-28",{"date":74,"type":23},{"date":546,"type":23},"2027-12-01",{"name":548,"class":52},"The Cleveland Clinic",{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":24,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":4},"100634225","integrating-care-for-hypertension-diabetes-multimorbidity-in-guatemala-through-hearts-implementation-100634225","NCT07536919","Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation","Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation (MULTI-HEARTS)","MULTI-HEARTS","Inclusion Criteria:\n\n* Age ≥18 years\n* Systolic blood pressure ≥130 mmHg on ≥2 occasions, defined as the mean of 6 measurements at 2 study visits scheduled at least 1 day apart but within 7 days\n* Hemoglobin A1c ≥6.5%\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Does not live in Health Center's catchment area or is unwilling to receive care at the Health Center\n* Currently pregnant or planning pregnancy in the next 2 years\n* Has been diagnosed with type 1 diabetes, or there is high suspicion of this diagnosis by study physicians\n* Has severe chronic or terminal illness such that primary care management of hypertension and\u002For diabetes would be clinically inappropriate, including end-stage kidney disease\n* Confined to bed\n* Planning to leave the study area in the next 2 years\n* Unwilling to comply with protocol requirements",{"count":558,"type":23},1440,[123],"The purpose of this study is to find out whether a program called HEARTS can improve care for people who have both high blood pressure and diabetes. HEARTS was created by the World Health Organization to help primary care clinics deliver better treatment. It includes training for health workers, simpler treatment guides, better access to medicines, teamwork among clinic staff, and tracking systems to monitor patient care. In this study, 36 public primary care clinics in Guatemala will be randomly assigned to either use the HEARTS program or continue with their current care. About 1,440 adults who have both high blood pressure and diabetes will take part. Participants will be assessed at the start of the study and again after 12 months. The main measures are blood pressure and hemoglobin A1c (a blood test that shows average blood sugar levels over the past 2 to 3 months).",[29,562],"Type 2 Diabetes","2026-04-12",{"date":565,"type":45},"2026-04-17",{"date":567,"type":23},"2027-05-01",{"date":569,"type":23},"2030-05-01",{"name":571,"class":52},"University of Michigan",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":18,"minAge":579,"maxAge":580,"enrollmentInfo":581,"targetDuration":4,"studyType":24,"phases":583,"briefSummary":584,"conditions":585,"keywords":586,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":112},"100633175","wearable-bp-wearable-everyday-automated-readings-to-enable-assessment-of-blood-pressure-control-100633175","NCT07523269","WEARABLE-BP: Wearable Everyday Automated Readings to Enable Assessment of Blood Pressure Control","WEARABLE-BP","Inclusion Criteria:\n\n* Adults aged 21 to 85 years.\n* Able to read and speak English.\n* Have an MGB provider and medical record number in EPIC\n* Study participants will wear the Aktiia bracelet for 6 months\n* Willing to attend two on-site study visits and comply with all study procedures.\n* Signed informed consent provided.\n* Own a smartphone with iOS or Android operating system.\n* Hypertensive with uncontrolled systolic blood pressure (SBP) \\>135 mm Hg by unattended automated office measurement\n* Currently taking 0, 1 or 2 antihypertensive medications.\n\nExclusion Criteria:\n\n* Severe hypertension (SBP \\> 180 mmHg or DBP \\> 120 mmHg).\n* Pregnant or breastfeeding.\n* Known severe heart failure (LVEF \\\u003C 35%).\n* Known severe valvular heart disease.\n* Known pheochromocytoma.\n* Known severe chronic kidney disease (CKD stage 4-5; eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Known uncontrolled hyperthyroidism or hypothyroidism.\n* Known severe diabetes (Hemoglobin A1c \\> 10%).\n* Known resting heart rate \\> 120 bpm.\n* Known persistent atrial fibrillation.\n* Known Raynaud's disease.\n* Known tremors or shivering disorders.\n* Known exfoliative skin diseases.\n* Known allergy to silicone.\n* Presence of lymphedema.\n* Paralysis of the arm.\n* Arm amputation.\n* Presence of implanted devices, such as a pacemaker, defibrillator, intravascular device, or arteriovenous fistula.\n* Upper arm circumference \\\u003C 22 cm or \\> 42 cm.\n* Wrist circumference \\> 23 cm.\n* Mastectomy","21 Years","85 Years",{"count":582,"type":23},164,[123],"The WEARABLE-BP study will evaluate the clinical value of obtaining continual measurements using the Aktiia G1 Optical Blood Pressure Monitoring (OBPM) device in hypertensive patients, compared to using a traditional upper arm cuff for home BP monitoring.\n\nThe WEARABLE-BP study aims to compare the change in unattended automated office blood pressure from baseline to 6 months between two study groups: those given an Aktiia G1 BP monitor and those given a traditional upper arm BP cuff.",[29],[587,588,68],"Vascular Diseases","Cardiovascular Diseases","2026-04-08",{"date":591,"type":45},"2026-04-13",{"date":593,"type":23},"2026-04",{"date":595,"type":23},"2027-12",{"name":597,"class":81},"Aktiia SA",{"id":599,"slug":600,"hasResults":12,"nctId":601,"briefTitle":602,"officialTitle":603,"acronym":604,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":60,"maxAge":4,"enrollmentInfo":606,"targetDuration":608,"studyType":93,"phases":4,"briefSummary":609,"conditions":610,"keywords":613,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":624,"completionDateStruct":626,"leadSponsor":627,"locationsCount":112},"100629868","homocysteine-and-early-diastolic-dysfunction-in-newly-diagnosed-hypertension-100629868","NCT07480265","Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension","Relationship Between Elevated Homocysteine Levels and Early Diastolic Dysfunction in Newly Diagnosed Hypertensive Patients","HHT-EDD","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Newly diagnosed essential hypertension within the previous 6 months\n* Ability and willingness to provide informed consent\n* Availability for clinical evaluation, laboratory testing, ambulatory blood pressure monitoring, electrocardiography, and transthoracic echocardiography\n\nExclusion Criteria:\n\n* Resistant hypertension\n* Secondary hypertension\n* Acute coronary syndrome within the previous 6 months\n* Major surgery within the previous 6 months\n* Known heart failure\n* Pulmonary hypertension\n* Congenital heart disease\n* Atrial fibrillation or atrial flutter\n* Moderate or severe valvular heart disease\n* Chronic kidney disease\n* Anemia\n* Current folate, vitamin B12, or vitamin B6 supplementation or treatment\n* Inadequate echocardiographic image quality for strain analysis\n* Known systemic conditions that may significantly affect plasma homocysteine levels",{"count":607,"type":23},500,"2 Years","This prospective single-center observational study aims to evaluate the relationship between elevated plasma homocysteine levels and early echocardiographic abnormalities in patients with newly diagnosed essential hypertension. Adult patients diagnosed with essential hypertension within the previous 6 months will undergo clinical assessment, ambulatory blood pressure monitoring, electrocardiography, laboratory testing, and comprehensive transthoracic echocardiography including diastolic function assessment and strain analysis when image quality is adequate. Participants will be classified according to plasma homocysteine level using, and patients with elevated and normal homocysteine levels will be compared with respect to diastolic dysfunction and left ventricular and left atrial global longitudinal strain parameters. Clinical, laboratory, and echocardiographic data will also be used to develop a machine-learning based model for prediction of H-type hypertension.",[29,611,612],"Hyperhomocysteinemia","Diastolic Dysfunction",[614,615,616,617,618,619,620],"H-type hypertension","Homocysteine","Echocardiography","Diastolic dysfunction","Left ventricular global longitudinal strain","Left atrial global longitudinal strain","Machine learning","2026-03-20",{"date":623,"type":45},"2026-03-24",{"date":625,"type":45},"2025-06-02",{"date":391,"type":23},{"name":628,"class":52},"Necmettin Erbakan University",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":200,"minAge":60,"maxAge":4,"enrollmentInfo":637,"targetDuration":4,"studyType":24,"phases":639,"briefSummary":640,"conditions":641,"keywords":644,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":647,"lastUpdatePostDateStruct":648,"startDateStruct":650,"completionDateStruct":652,"leadSponsor":654,"locationsCount":4},"100602762","remote-physical-activity-intervention-for-high-blood-pressure-postpartum-100602762","NCT07127731","REmote Physical ACtivity Intervention for High Blood Pressure Postpartum","REACH BP: REmote Physical ACtivity Intervention for High Blood Pressure Postpartum","REACH BP","Inclusion Criteria:\n\n* Delivery of a live birth at Northwestern Medicine 6-12 weeks prior\n* Systolic blood pressure 120-139 or diastolic blood pressure 80-89 during the first 20 weeks of gestation\n* Low self-reported physical activity levels\n* Able to access the internet at least weekly\n* Have patient portal account or willing to set one up\n* Willing to wear a FitBit\n* Spoken and written English or Spanish language fluency\n\nExclusion Criteria:\n\n* Medical contraindications to participating in a structured physical activity program\n* Currently participating in a structured physical activity or weight loss program\n* Hypertensive disorder of pregnancy (e.g., preeclampsia, gestational hypertension, eclampsia)",{"count":638,"type":23},60,[123],"The purpose of this intervention is to help new mothers who had elevated blood pressure during pregnancy become more physically active after birth. The investigators will connect data from FitBits to the electronic health record. Women will then get weekly messages with feedback and goals to help them stay active. The investigators will test if the intervention improves step counts and blood pressure after pregnancy. The investigators will also test if the intervention is feasible and enjoyed by postpartum women.",[29,642,643],"Hypertension ,Pregnancy","Physical Activity",[209,645,513,646],"pregnancy","physical activity","2026-03-19",{"date":649,"type":45},"2026-03-23",{"date":651,"type":23},"2027-04",{"date":653,"type":23},"2028-04",{"name":655,"class":52},"Northwestern University",{"id":657,"slug":658,"hasResults":12,"nctId":659,"briefTitle":660,"officialTitle":660,"acronym":4,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":18,"minAge":662,"maxAge":663,"enrollmentInfo":664,"targetDuration":4,"studyType":24,"phases":666,"briefSummary":667,"conditions":668,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":677,"locationsCount":4},"100630793","empirical-study-on-lifestyle-intervention-for-elderly-hypertensive-patients-in-community-based-on-ttm-theory-100630793","NCT07492290","Empirical Study on Lifestyle Intervention for Elderly Hypertensive Patients in Community Based on TTM Theory","Inclusion Criteria:\n\n1. Patients whose blood pressure measurements taken at community hospitals meet the hypertension criteria outlined in the Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision);\n2. Aged 60-75 years old;\n3. Have certain abilities in reading, comprehension, and communication;\n4. Able to use a smartphone;\n5. In the pre-conscious\u002Fconscious\u002Fpreparatory stage.\n6. Volunteer to participate in this study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Exclude those with a history of severe heart, brain, kidney diseases or cancer;\n2. Patients who currently have or have previously had mental disorders;\n3. Patients who are currently participating in other research projects.","60 Years","75 Years",{"count":665,"type":23},106,[123],"This study intervention is based on TTM theory and implements lifestyle interventions, including nutritious diet, regular exercise, social support, sleep optimization, avoidance of addictive substances, and stress management. Through various means such as training, guidance, and motivation, motivation is formed, goals are determined, and habits are strengthened, ultimately leading to the development of a healthy lifestyle, control of blood pressure indicators, and improvement of quality of life and cognitive function. The intervention period is a total of 3 weeks, on line.",[29,669],"Age More 60yr","2026-03-18",{"date":672,"type":45},"2026-03-25",{"date":674,"type":23},"2026-04-01",{"date":676,"type":23},"2026-12-30",{"name":678,"class":52},"Qu Shen"]